Anti-tumor activity of CCI-779 in papillary renal cell cancer
View Patent ↗This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.
1. A method of treating papillary renal cell carcinoma in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCI-779, wherein said papillary renal cell carcinoma is metastatic.
2. The method according to claim 1 , wherein the papillary renal cell carcinoma is hereditary type I papillary renal cell carcinoma.
3. The method according to claim 1 , wherein the papillary renal cell carcinoma is hereditary type II papillary renal cell carcinoma.
4. The method according to claim 1 , wherein the papillary renal cell carcinoma is sporadic papillary renal cell carcinoma.
5. The method according to claim 1 , wherein the papillary renal cell carcinoma is previously untreated papillary renal cell carcinoma.
6. The method according to claim 1 , wherein the papillary renal cell carcinoma is advanced.
7. The method according to claim 1 , wherein the CCI-779 is administered intravenously.
8. The method according to claim 1 , wherein the CCI-779 is administered weekly for one to 24 months.
9. The method according to claim 1 , wherein the CCI-779 is administered intravenously at a dose of 1 to 250 mg per week.
10. The method according to claim 9 , wherein the CCI-779 is administered intravenously at a dose of 25 mg per week.
11. The method according to claim 1 , wherein the CCI-779 is the sole anti-neoplastic agent in the regimen.
12. The method according to claim 1 , wherein the CCI-779 is the sole active agent in the regimen.
13. The method according to claim 1 , further comprising a further active agent, provided that the further active agent is not an interferon.
14. A method of treating papillary renal cell carcinoma in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCI-779 in the absence of interferon alpha.